Avascular Necrosis Treatment in India & UAE — From Core Decompression to Joint Replacement

Avascular necrosis treatment in India from $3,000. Core decompression, bone grafting & joint replacement for AVN of hip, knee & shoulder. Expert orthopaedic teams. Book with GAF Healthcare.

Estimated cost: $3,000 – $8,000 · Average stay: 5–10 days

Avascular necrosis (AVN) — also called osteonecrosis — is the death of bone tissue from disruption of its blood supply. Without adequate blood flow, the bone cells (osteocytes) die, the bone becomes structurally weak, and the overlying articular cartilage eventually collapses — leading to severe joint destruction and debilitating arthritis. AVN most commonly affects the femoral head (the ball of the hip joint), but also occurs in the humeral head (shoulder), knee (distal femur and proximal tibia), and talus (ankle).

AVN is a diagnosis that often strikes relatively young patients — the average age at diagnosis is 35–45 years — because many of its most common causes affect young adults: corticosteroid use (the most common non-traumatic cause in India and globally, often associated with treatment for autoimmune conditions, organ transplant, or nephrotic syndrome); alcohol misuse; sickle cell disease; systemic lupus erythematosus; decompression sickness (in divers and workers in hyperbaric environments); and haematological conditions.

India has high expertise in managing AVN, partly because corticosteroid-related AVN is highly prevalent in the Indian patient population due to the widespread use of steroids for various medical conditions. India's orthopaedic centres offer the full spectrum of AVN management — from early-stage conservative and surgical joint-preservation techniques through to total joint replacement for advanced disease.

AVN Stages and Diagnosis

AVN is staged by the ARCO (Association Research Circulation Osseous) classification, which guides treatment. Stage 0 — normal X-ray and MRI (diagnosed only on biopsy); Stage I — abnormal MRI (sclerosis or oedema pattern) but normal X-ray; Stage II — sclerotic or lucent changes visible on X-ray but no crescent sign or collapse; Stage III — crescent sign (subchondral fracture visible on X-ray or MRI) — the critical juncture where the joint surface is about to collapse; Stage IV — femoral head collapse with joint space narrowing and acetabular involvement (end-stage arthritis).

MRI is the gold standard for early AVN diagnosis — it is 99% sensitive even in Stage I disease, when plain X-rays are completely normal. MRI shows the classic "double-line sign" of AVN (a high-signal inner border and a low-signal outer border representing the reactive interface between viable and necrotic bone). Bilateral MRI of both hips is recommended even when only one side is symptomatic, because bilateral involvement is present in 40–80% of non-traumatic AVN cases.

The most critical clinical decision point is Stage III — once the crescent sign appears (indicating subchondral fracture), collapse is inevitable without intervention. Joint-preserving procedures are most effective at Stages I–II; at Stage III, their results are less predictable; at Stage IV, joint replacement is the only effective option.

AVN Treatment Procedures

Core decompression is the most widely used joint-preserving procedure for early-stage AVN (Stages I–IIB). A 6–9 mm cannulated drill is passed through the lateral cortex of the femur under fluoroscopic (X-ray) guidance to reach the necrotic zone of the femoral head, removing a cylinder of bone. This decompression reduces the elevated intraosseous pressure that contributes to ischaemia and is believed to stimulate the ingrowth of new blood vessels and bone healing. Core decompression is performed as a day procedure under general or spinal anaesthesia; the patient is partial weight-bearing for 6 weeks. Success rates (avoidance of collapse) of 65–90% are reported in Stage I–IIA disease.

Bone grafting procedures enhance core decompression by filling the decompressed tunnel with graft material to provide structural support to the overlying articular cartilage. Vascularised fibular graft (VFG) transplants a segment of the fibula (the non-weight-bearing leg bone) with its blood supply (peroneal vessels) into the femoral head necrotic zone using microsurgical vessel anastomosis. VFG provides both structural support and a new blood supply to the necrotic zone — the best reported outcomes in younger patients with large lesions. The procedure is technically demanding (6–8 hours of microsurgery) but offers the best chance of hip preservation in Stage II–IIIA disease.

Non-vascularised bone graft (using cancellous bone from the iliac crest, or synthetic bone substitutes like tricalcium phosphate) is a simpler alternative that provides structural support without microsurgery, used for smaller or less aggressive lesions.

Tantalum rod implantation places a porous trabecular metal (tantalum) rod into the necrotic zone to provide structural support — an intermediate-complexity option between core decompression alone and vascularised graft.

Total hip replacement (THR) is the definitive treatment for Stage IV AVN — or for Stage III disease in older patients where joint preservation has failed or is not appropriate. THR for AVN in young patients is challenging because the implants must last decades. High-quality implant bearing surfaces (ceramic-on-ceramic, highly cross-linked polyethylene) and uncemented acetabular and femoral components are preferred in young AVN patients to maximise implant longevity.

Procedure Steps

1. MRI bilateral hips; bone density scan; haematological and coagulation work-up; ARCO staging
2. Treatment of underlying cause (reduce/stop corticosteroids if possible; address sickle cell, SLE)
3. Core decompression ± bone graft / tantalum rod for Stage I–III (joint preserving)
4. Vascularised fibular graft for large Stage II–IIIA lesions in suitable younger patients
5. Protected weight-bearing post-procedure; MRI at 6 months to assess healing
6. Total hip replacement for Stage IV or failed joint preservation

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

USA — $10,000 – $30,000 — Save up to 80%

UK — £6,000 – £20,000 — Save up to 75%

UAE — $8,000 – $20,000 — Save up to 70%

India — $3,000 – $8,000 — Best value

Core decompression for AVN in India costs $3,000–$5,000. Vascularised fibular graft costs $6,000–$10,000. Total hip replacement for Stage IV AVN costs $5,000–$8,000. In the USA, equivalent costs are $15,000–$30,000 (core decompression) and $25,000–$50,000 (THR). India's expertise in vascularised fibular graft is particularly strong at specialist microsurgery centres.

Recovery & Follow-up

Recovery from core decompression: partial weight-bearing on crutches for 6 weeks; normal activity at 3 months; MRI at 6 months. Recovery from vascularised fibular graft: 10–14 days in hospital; crutches for 3 months; full weight-bearing at 4 months; total recovery 6–12 months. Recovery from THR for AVN follows the same pattern as THR for OA — full weight-bearing from day 1, hospital discharge day 3–5, return to full activity at 3 months.

Recovery Tips

• Adhere strictly to the partial weight-bearing restriction after joint-preserving procedures — premature full weight-bearing causes collapse
• Avoid corticosteroids during the recovery period if at all possible — continued steroid exposure impairs healing and risks the contralateral hip
• Attend MRI follow-up at 6 months — this is the most important measure of whether the joint-preserving procedure has succeeded
• Maintain a healthy weight — excess body weight significantly increases the loading on the affected hip
• Report any sudden increase in hip pain immediately — this may indicate collapse and requires urgent imaging

Risks & Complications

Core decompression risks include: failure of joint preservation requiring conversion to THR (30–40% within 5 years in Stage II disease, higher in more advanced stages); subtrochanteric fracture (through the drill hole — requires internal fixation); infection. VFG risks include all core decompression risks plus microsurgical vessel anastomosis failure (2–5%), peroneal nerve injury at the donor leg (foot drop — most cases recover), fibula donor site discomfort, and wound healing problems. THR risks include infection, DVT/PE, dislocation, leg length discrepancy, periprosthetic fracture, and implant loosening.

Why GAF Healthcare

GAF Healthcare has specific expertise in AVN management referrals, recognising that this is a condition where early diagnosis and stage-appropriate treatment — in hands that perform these procedures regularly — significantly affects long-term joint preservation rates. We connect patients with India's orthopaedic centres that have dedicated AVN programmes including vascularised fibular graft microsurgery capability.

Frequently Asked Questions

How quickly does AVN progress to joint collapse?

The rate of progression varies considerably between patients and depends on the underlying cause, lesion size, and whether treatment is initiated. Without treatment, Stage I–II AVN progresses to femoral head collapse in approximately 80% of cases within 2 years. With core decompression, progression is delayed or prevented in 60–90% of Stage I–IIA cases. This is why early diagnosis (before the crescent sign — before Stage III) is so important — joint-preserving treatment options are significantly more effective in earlier stages.

Can I still have a total hip replacement if joint-preserving treatment fails?

Yes. If core decompression or vascularised graft fails (the femoral head collapses despite treatment), total hip replacement remains the definitive treatment and provides excellent pain relief and functional restoration. The previous joint-preserving procedure does not compromise the technical conduct of subsequent THR, though it is technically slightly more complex due to the previous bone graft within the femoral head. At India's high-volume arthroplasty centres, this complexity is routinely managed.

Is AVN of the hip the same in both hips? Do I need both treated?

AVN is bilateral in 40–80% of non-traumatic cases (corticosteroid-related, alcohol-related, sickle cell). Both hips should be imaged with MRI at the time of diagnosis even if only one is symptomatic — early treatment of the asymptomatic contralateral hip at Stage I–II prevents collapse on both sides. Many patients benefit from simultaneous bilateral core decompression in the same anaesthetic session, avoiding two separate recovery periods.